156 related articles for article (PubMed ID: 14769135)
1. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Laterra JJ; Grossman SA; Carson KA; Lesser GJ; Hochberg FH; Gilbert MR;
Neuro Oncol; 2004 Jan; 6(1):15-20. PubMed ID: 14769135
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S
Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
[TBL] [Abstract][Full Text] [Related]
4. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
[TBL] [Abstract][Full Text] [Related]
5. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
7. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
10. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
[TBL] [Abstract][Full Text] [Related]
12. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
[TBL] [Abstract][Full Text] [Related]
13. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
[TBL] [Abstract][Full Text] [Related]
15. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
17. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
19. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.
Fabi A; Mirri A; Felici A; Vidiri A; Pace A; Occhipinti E; Cognetti F; Arcangeli G; Iandolo B; Carosi MA; Metro G; Carapella CM
J Neurooncol; 2008 Mar; 87(1):79-84. PubMed ID: 17987263
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
